Share-based Payment Arrangement, Expense of PROKIDNEY CORP. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PROKIDNEY CORP. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • PROKIDNEY CORP. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $6,675,000, a 3.7% decline year-over-year.
  • PROKIDNEY CORP. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $26,581,000, a 66% increase year-over-year.
  • PROKIDNEY CORP. annual Share-based Payment Arrangement, Expense for 2024 was $29,372,000, a 4.8% decline from 2023.
  • PROKIDNEY CORP. annual Share-based Payment Arrangement, Expense for 2023 was $30,846,000, a 59% decline from 2022.
  • PROKIDNEY CORP. annual Share-based Payment Arrangement, Expense for 2022 was $74,469,000, a 10554% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PROKIDNEY CORP. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $26,581,000 $6,675,000 -$259,000 -3.7% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $26,840,000 $6,540,000 -$1,268,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $28,108,000 $6,416,000 -$1,264,000 -16% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $29,372,000 $6,950,000 +$13,319,000 01 Oct 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
Q3 2024 $16,053,000 $6,934,000 -$6,059,000 -47% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $22,112,000 $7,808,000 -$3,394,000 -30% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $25,506,000 $7,680,000 -$5,340,000 -41% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $30,846,000 $6,369,000 -$15,308,000 -171% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $46,154,000 $12,993,000 +$8,149,000 +168% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $38,005,000 $11,202,000 +$3,202,000 +40% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $34,803,000 $13,020,000 -$39,666,000 -75% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $74,469,000 $8,939,000 01 Oct 2022 31 Dec 2022 10-K 17 Mar 2025 2024 FY
Q3 2022 $4,844,000 +$4,844,000 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $8,000,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $52,686,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $0 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q3 2021 $175,000 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3

PROKIDNEY CORP. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $29,372,000 -$1,474,000 -4.8% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
2023 $30,846,000 -$43,623,000 -59% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 $74,469,000 +$73,770,000 +10554% 01 Jan 2022 31 Dec 2022 10-K 17 Mar 2025 2024 FY
2021 $699,000 -$31,000 -4.2% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2024 2023 FY
2020 $730,000 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.